佰金生命科学控股有限公司（01466）于2026年3月4日发布截至2026年2月28日的月报表。公告显示，公司法定/注册股本仍为10,000,000,000股，面值每股0.02港元，总额维持在200,000,000港元，与上月保持一致。
截至本月末，公司已发行普通股数量为932,254,085股，较上月无新增发行、无回购或注销记录。本月亦无股份期权、权证及可换股票据的变动事项。公司确认其已遵守上市规则及适用法律法规的要求。
公告由董事张诗敏签署。
佰金生命科学控股有限公司（01466）于2026年3月4日发布截至2026年2月28日的月报表。公告显示，公司法定/注册股本仍为10,000,000,000股，面值每股0.02港元，总额维持在200,000,000港元，与上月保持一致。
截至本月末，公司已发行普通股数量为932,254,085股，较上月无新增发行、无回购或注销记录。本月亦无股份期权、权证及可换股票据的变动事项。公司确认其已遵守上市规则及适用法律法规的要求。
公告由董事张诗敏签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.